A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
A phase 3 trial of Fianlimab, Cemiplimab, Nivolumab in melanoma, run by Regeneron Pharmaceuticals, now recruiting.
Overview
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) is a phase 3 interventional study registered as NCT06246916 by Regeneron Pharmaceuticals, with 560 participants planned, started 2024-09-09 and due to reach its primary completion in 2027-03-22. Interventions recorded: fianlimab, cemiplimab, relatlimab+nivolumab. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
Shares Fianlimab, Cemiplimab, Regeneron, Melanoma.
- TrialA Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back Af
Shares Fianlimab, Cemiplimab, Regeneron, Melanoma.
- TrialA Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous
Shares Fianlimab, Cemiplimab, Regeneron.
- TrialA Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small
Shares Fianlimab, Cemiplimab, Regeneron.
- TrialA First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Hav
Shares Cemiplimab, Regeneron, Melanoma.
- TrialNeoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients
Shares Fianlimab, Cemiplimab, Regeneron.
- TrialA Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
Shares Relatlimab + nivolumab, Nivolumab, Melanoma.
- TrialA Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed
Shares Relatlimab + nivolumab, Nivolumab, Melanoma.